Virtus Biotech ETF
BBP
21 hedge funds and large institutions have $15.1M invested in Virtus Biotech ETF in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 2 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5% more funds holding
Funds holding: 20 → 21 (+1)
0.53% more ownership
Funds ownership: 42.67% → 43.2% (+0.53%)
7% less capital invested
Capital invested by funds: $16.2M → $15.1M (-$1.17M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$774K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$232K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$213K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$83.3K |
| 5 |
SMG
Smart Money Group
Eastland,
Texas
|
+$59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$1.08M |
| 2 |
LPL Financial
San Diego,
California
|
-$148K |
| 3 |
APA
American Portfolios Advisors
Holbrook,
New York
|
-$51.8K |
| 4 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$41.2K |
| 5 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
-$9K |
BBP Hedge Fund Activity: Q2 2019 in Review
21 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q2 2019, worth a combined $15.1M — down 7.2% from $16.2M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BBP positions and 2 closed out — a net gain of 1 holder — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $774K. The largest seller was Jane Street, cutting an estimated $1.08M.
- 21 institutional investors held Virtus Biotech ETF (BBP) as of Q2 2019, up from 20 in Q1 2019.
- Funds reported $15.1M of Virtus Biotech ETF stock for Q2 2019, down 7.2% quarter-over-quarter.
- 3 funds opened new Virtus Biotech ETF positions in Q2 2019 and 2 closed out, a net change of +1 holder.
- The largest Virtus Biotech ETF buyer in Q2 2019 was Royal Bank of Canada, an estimated $774K added.
- The largest Virtus Biotech ETF seller in Q2 2019 was Jane Street, an estimated $1.08M sold.
Based on aggregated 13F filings for Q2 2019.